Indicator summary: Neutral (2 bullish, 2 bearish, 1 neutral). As of 2026-11-05, the close was $247.18: 7.8% below the 50-day average and 23.5% above the 200-day average, which is rising. RSI (14) is 34, in its neutral range. MACD is bearish. The stock sits 70% of the way up its 52-week range of $124.59 to $299.39, on 1.3x its 20-day average volume.
| Indicator | Reading | Read |
|---|---|---|
| 50-day average | $268.05 | Price 7.8% below |
| 200-day average | $200.15 | Price 23.5% above, average rising |
| 50 vs 200-day | 50 above 200 | Golden-cross alignment |
| RSI (14) | 34 | Neutral range |
| MACD (12, 26, 9) | -1.46 vs +3.28 | Line below signal |
| 52-week range | $124.59 to $299.39 | 70% of the way up the range |
| Volume vs 20-day average | 1.3x | Normal |
Base rates use PSX's own daily history since 2012; they describe the past, not a forecast.
As of 2026-11-05, PSX's 14-day RSI is 34, which is in the neutral range between 30 and 70.
Yes. PSX closed at $247.18 on 2026-11-05, 23.5% above its 200-day average of $200.15, which is rising. When it closed above its 200-day average (2,288 days), it was higher 63 trading days later 60% of the time, median +3.1%.
No. PSX closed at $247.18 on 2026-11-05, 7.8% below its 50-day average of $268.05. When it closed below its 50-day average (1,412 days), it was higher 63 trading days later 66% of the time, median +5.7%.
No cross in the last 10 trading days. As of 2026-11-05 the MACD line is -1.46 against a signal line of +3.28, so MACD is bearish.
No. At $247.18 it sits 70% of the way up its 52-week range of $124.59 to $299.39, 17.4% below the high.
Neutral: 2 of 5 indicators are bullish and 2 bearish as of 2026-11-05 (the 50 and 200-day averages, their alignment, RSI and MACD). A rating summarises the chart; it is not a recommendation.
ŷRobot chart signal: Hold, from the chart signal model.
PSX analysis: AI score, fair value and forecast · Is it a bull or a bear market today? · All covered stocks
ŷRobot analysis is AI-generated and quality-gated; nothing here is investment advice.